Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress
Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and…
Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025
October 25, 2025 11:01 ET | Source: Cullinan Therapeutics, Inc. CLN-978 led…
